Vanda Pharmaceuticals (NASDAQ:VNDA) will be releasing its earnings data after the market closes on Wednesday, February 14th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.11) per share for the quarter.
Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) opened at $15.65 on Wednesday. The stock has a market cap of $703.12, a price-to-earnings ratio of -48.91 and a beta of 1.23. Vanda Pharmaceuticals has a fifty-two week low of $11.90 and a fifty-two week high of $18.99.
Several brokerages have issued reports on VNDA. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 19th. Oppenheimer set a $26.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 29th. Seaport Global Securities began coverage on shares of Vanda Pharmaceuticals in a report on Friday, January 19th. They issued a “buy” rating and a $20.00 target price on the stock. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, ValuEngine lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $21.29.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.